Li Med Labs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-11-2024
- Paid Up Capital ₹ 1.10 M
as on 15-11-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.50 M
as on 15-11-2024
- Revenue 20.99%
(FY 2023)
- Profit -10.17%
(FY 2023)
- Ebitda -0.67%
(FY 2023)
- Net Worth 40.62%
(FY 2023)
- Total Assets 14.78%
(FY 2023)
About Li Med Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.10 M.
The company currently has active open charges totaling ₹7.50 M.
Shafi Ayush, Musthafa Ibrahim, Sumaiya Aasmi, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U74999KL2018PTC053797
- Company No.
053797
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thiruvananthapuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Li Med Labs?
Board Members(10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shafi Ayush  | Whole-Time Director | 05-Feb-2019 | Current |
| Musthafa Ibrahim | Whole-Time Director | 05-Feb-2019 | Current |
| Sumaiya Aasmi | Director | 05-Feb-2019 | Current |
| Hussain Sithara | Director | 05-Feb-2019 | Current |
| Mithun Anver | Whole-Time Director | 05-Feb-2019 | Current |
| Venpala Kavitha | Director | 05-Feb-2019 | Current |
Financial Performance of Li Med Labs.
Li Med Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.99% increase. The company also saw a substantial fall in profitability, with a 10.17% decrease in profit. The company's net worth Soared by an impressive increase of 40.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Li Med Labs?
In 2023, Li Med Labs had a promoter holding of 18.18% and a public holding of 81.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Li Med Pharma Private LimitedActive 2 years 5 monthsShafi Ayush, Musthafa Ibrahim and 3 more are mutual person
- Penta Holidays Private LimitedActive 2 years 7 months
Sumaiya Aasmi, Hussain Sithara and 4 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Feb 2020 | ₹7.50 M | Open |
How Many Employees Work at Li Med Labs?
Unlock and access historical data on people associated with Li Med Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Li Med Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Li Med Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
